We developed a real time reverse transcriptase polymerase chain reaction (RT-PCR) assay system for detecting the MOZ-CBP fusion transcript and used it to monitor minimal residual disease (MRD) status in a patient with therapy related acute myeloid leukemia (t-AML) harboring t(8;16)(p11;p13). Expression of the MOZ-CBP fusion transcript was determined by RT-PCR analysis of the patient’s bone marrow at the time of diagnosis. Thereafter, real time RT-PCR was used to evaluate MRD levels throughout the entire course of treatment. The sensitivity of quantitative RT-PCR for the MOZ-CBP fusion transcript was 10−5. Below this level, MRD was classified as negative. Real time RT-PCR of the bone marrow after induction therapy showed the reduction of MOZ-CBP transcript to approximately 10−3 level when compared to the diagnostic sample. MRD was classified as negative (<10−5 compared with that in the bone marrow at diagnosis) after 5 courses of chemotherapy, a level that was maintained post-allo-hematopoietic stem cell transplantation. Real time RT-PCR of the MOZ-CBP transcript is a useful tool for assessing MRD status for a patient with therapy related acute myeloid leukemia who was initially predicted to have a poor prognosis.
*Department of Pediatrics, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto
†Department of Pediatrics, Matsushita Memorial Hospital, Moriguchi, Japan
This work was supported by a grant from the Ministry of Education, Sports, Science and Technology.The authors declare no conflict of interest.
Reprints: Toshihiko Imamura, MD, Department of Pediatrics, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, 465 Kajii-cho, Hirokoji, Kamigyo-ku, Kyoto, Japan 602-8566 (e-mail: email@example.com).
Received March 28, 2011
Accepted September 19, 2011